A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation

Welcome to the Afibber’s Forum

Serving Afibbers worldwide since 1999

Moderated by Shannon and Carey

Forum List Message List New Topic

sldabrowski

A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - American College of Cardiolog
November 28, 2023 03:13AM

Registered: 3 years ago
Posts: 190

Some good news for those on NOAC. New drug - Clinical trials were stopped early because of good outcomes. Not sure when it will be ready for patients.

[www.acc.org]

Press Release: Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation.

Reply Quote

mjamesone

Re: A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - American College of Cardiolog
December 16, 2023 07:02PM

Registered: 7 years ago
Posts: 253

Yes, potentially very good news. They definitely proved that bleeding risk is significantly reduced vs NOAC's, but they still have to prove that stroke risk will be acceptable vs current NOAC's. That would be another trial, so probably a bit of a wait.

Jim